Oncolytic measles virus-based delivery systems

Pavlos Msaouel, Evanthia Galanis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The majority of advanced malignancies remain incurable despite the considerable progress that has been achieved in recent years. Thus, novel treatment modalities are urgently required. Oncolytic virotherapy represents one such potential strategy that harnesses the propensity of certain viruses to selectively invade and lyse cancer tissues [1]. Such viruses have developed, over millennia of adaptive evolution, multiple diverse mechanisms that allow efficient invasion of human tissues and usurpation of the cellular biosynthetic machinery. Oncolytic, replication-competent viruses specifically invade and proliferate within malignant cells, resulting in the release of viral progeny that further facilitates the spread of the infection to adjacent cells. Therefore, in contrast to other anticancer strategies, the oncolytic effect of the initial replicative virus dose can be self-amplified over time.

Original languageEnglish (US)
Title of host publicationGene and Cell Therapy
Subtitle of host publicationTherapeutic Mechanisms and Strategies, Fourth Edition
PublisherCRC Press
Pages157-174
Number of pages18
ISBN (Electronic)9781466572003
ISBN (Print)9781466571990
DOIs
StatePublished - Jan 1 2015

Fingerprint

Oncolytic Viruses
Measles virus
Viruses
Oncolytic Virotherapy
Tissue
Virus Replication
Neoplasms
Machinery
Infection
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Msaouel, P., & Galanis, E. (2015). Oncolytic measles virus-based delivery systems. In Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Fourth Edition (pp. 157-174). CRC Press. https://doi.org/10.1201/b18002

Oncolytic measles virus-based delivery systems. / Msaouel, Pavlos; Galanis, Evanthia.

Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Fourth Edition. CRC Press, 2015. p. 157-174.

Research output: Chapter in Book/Report/Conference proceedingChapter

Msaouel, P & Galanis, E 2015, Oncolytic measles virus-based delivery systems. in Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Fourth Edition. CRC Press, pp. 157-174. https://doi.org/10.1201/b18002
Msaouel P, Galanis E. Oncolytic measles virus-based delivery systems. In Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Fourth Edition. CRC Press. 2015. p. 157-174 https://doi.org/10.1201/b18002
Msaouel, Pavlos ; Galanis, Evanthia. / Oncolytic measles virus-based delivery systems. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Fourth Edition. CRC Press, 2015. pp. 157-174
@inbook{e777f15d8d684a6ca83c448570ac1134,
title = "Oncolytic measles virus-based delivery systems",
abstract = "The majority of advanced malignancies remain incurable despite the considerable progress that has been achieved in recent years. Thus, novel treatment modalities are urgently required. Oncolytic virotherapy represents one such potential strategy that harnesses the propensity of certain viruses to selectively invade and lyse cancer tissues [1]. Such viruses have developed, over millennia of adaptive evolution, multiple diverse mechanisms that allow efficient invasion of human tissues and usurpation of the cellular biosynthetic machinery. Oncolytic, replication-competent viruses specifically invade and proliferate within malignant cells, resulting in the release of viral progeny that further facilitates the spread of the infection to adjacent cells. Therefore, in contrast to other anticancer strategies, the oncolytic effect of the initial replicative virus dose can be self-amplified over time.",
author = "Pavlos Msaouel and Evanthia Galanis",
year = "2015",
month = "1",
day = "1",
doi = "10.1201/b18002",
language = "English (US)",
isbn = "9781466571990",
pages = "157--174",
booktitle = "Gene and Cell Therapy",
publisher = "CRC Press",

}

TY - CHAP

T1 - Oncolytic measles virus-based delivery systems

AU - Msaouel, Pavlos

AU - Galanis, Evanthia

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The majority of advanced malignancies remain incurable despite the considerable progress that has been achieved in recent years. Thus, novel treatment modalities are urgently required. Oncolytic virotherapy represents one such potential strategy that harnesses the propensity of certain viruses to selectively invade and lyse cancer tissues [1]. Such viruses have developed, over millennia of adaptive evolution, multiple diverse mechanisms that allow efficient invasion of human tissues and usurpation of the cellular biosynthetic machinery. Oncolytic, replication-competent viruses specifically invade and proliferate within malignant cells, resulting in the release of viral progeny that further facilitates the spread of the infection to adjacent cells. Therefore, in contrast to other anticancer strategies, the oncolytic effect of the initial replicative virus dose can be self-amplified over time.

AB - The majority of advanced malignancies remain incurable despite the considerable progress that has been achieved in recent years. Thus, novel treatment modalities are urgently required. Oncolytic virotherapy represents one such potential strategy that harnesses the propensity of certain viruses to selectively invade and lyse cancer tissues [1]. Such viruses have developed, over millennia of adaptive evolution, multiple diverse mechanisms that allow efficient invasion of human tissues and usurpation of the cellular biosynthetic machinery. Oncolytic, replication-competent viruses specifically invade and proliferate within malignant cells, resulting in the release of viral progeny that further facilitates the spread of the infection to adjacent cells. Therefore, in contrast to other anticancer strategies, the oncolytic effect of the initial replicative virus dose can be self-amplified over time.

UR - http://www.scopus.com/inward/record.url?scp=85053972522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053972522&partnerID=8YFLogxK

U2 - 10.1201/b18002

DO - 10.1201/b18002

M3 - Chapter

SN - 9781466571990

SP - 157

EP - 174

BT - Gene and Cell Therapy

PB - CRC Press

ER -